# Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

> **NCT03076437** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shenzhen Institute for Innovation and Translational Medicine** · enrollment: 28 (actual)

## Conditions studied

- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Lymphoma

## Interventions

- **COMBINATION_PRODUCT:** Drugs and Anti-CD19-CAR transduced T cells

## Key facts

- **NCT ID:** NCT03076437
- **Lead sponsor:** Shenzhen Institute for Innovation and Translational Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-15
- **Primary completion:** 2019-05-26
- **Final completion:** 2019-12-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03076437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03076437, "Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03076437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*